Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 5, Pages 1690
Publisher
MDPI AG
Online
2020-03-03
DOI
10.3390/ijms21051690
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of systemic treatments in psoriatic arthritis. A systematic review, meta-analysis and GRADE evaluation
- (2019) C Dressler et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Hyperglycemia is associated with psoriatic inflammation in both humans and mice
- (2019) Kyoko Ikumi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
- (2019) Youssef A Elnabawi et al. CARDIOVASCULAR RESEARCH
- Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator–controlled phase 3 AMAGINE-2 trial
- (2019) Luis Puig et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis
- (2019) Chenyang Lu et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
- (2019) Laura M. Sawyer et al. PLoS One
- Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
- (2019) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
- (2019) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials
- (2019) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome
- (2018) Irène Gallais Sérézal et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
- (2018) Philip J. Mease et al. JOURNAL OF RHEUMATOLOGY
- Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- (2018) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections
- (2018) Shivani B. Kaushik et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
- (2018) Farzad Alinaghi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study
- (2018) Carle Paul et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
- (2018) Elizabeth G. Araujo et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions
- (2018) Peter Foley et al. JAMA Dermatology
- Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
- (2018) Dominique Baeten et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Network meta-analyses of systemic treatments for psoriasis: a critical appraisal
- (2018) A.G. Ellis et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks
- (2018) Esther von Stebut et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response
- (2018) L.M. Sawyer et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients
- (2018) Koen Venken et al. Nature Communications
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
- (2018) Jasvinder A. Singh et al. Arthritis & Rheumatology
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
- (2017) Bruce E. Sands et al. GASTROENTEROLOGY
- CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin
- (2017) Stanley Cheuk et al. IMMUNITY
- “Inflammatory skin march” in atopic dermatitis and psoriasis
- (2017) Masutaka Furue et al. INFLAMMATION RESEARCH
- Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)
- (2017) Shinichi Imafuku et al. JOURNAL OF DERMATOLOGY
- Safety of biologics in psoriasis
- (2017) Masahiro Kamata et al. JOURNAL OF DERMATOLOGY
- Pathogenesis of psoriasis and development of treatment
- (2017) Eisaku Ogawa et al. JOURNAL OF DERMATOLOGY
- Dynamic Changes in Resident and Infiltrating Epidermal Dendritic Cells in Active and Resolved Psoriasis
- (2017) Elisa Martini et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome
- (2017) Milton José Max Rodríguez-Zúñiga et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis and suicidality: A systematic review and meta-analysis
- (2017) Sanminder Singh et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis and comorbid diseases
- (2017) Junko Takeshita et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate
- (2017) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Enthesitis: from pathophysiology to treatment
- (2017) Georg Schett et al. Nature Reviews Rheumatology
- Psoriatic Arthritis
- (2017) Christopher T. Ritchlin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
- (2017) P. Kawalec et al. RHEUMATOLOGY INTERNATIONAL
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
- (2016) Hidehisa Saeki et al. JOURNAL OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis
- (2015) Kasper Fjellhaugen Hjuler et al. AMERICAN JOURNAL OF MEDICINE
- The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
- (2015) Florence J. Dalgard et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy
- (2014) A.M. Tobin et al. BRITISH JOURNAL OF DERMATOLOGY
- Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
- (2014) S. Cheuk et al. JOURNAL OF IMMUNOLOGY
- Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
- (2014) Charles W. Lynde et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin
- (2013) B. Dyring-Andersen et al. BRITISH JOURNAL OF DERMATOLOGY
- Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ ILC3 in Psoriasis
- (2013) Federica Villanova et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis
- (2013) Emmilia A. Dowlatshahi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta‐Analysis of Observational Studies
- (2013) Ehrin J. Armstrong et al. Journal of the American Heart Association
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Diagnosis and classification in spondyloarthritis: identifying a chameleon
- (2012) Astrid van Tubergen et al. Nature Reviews Rheumatology
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
- (2011) Wolf-Henning Boehncke et al. EXPERIMENTAL DERMATOLOGY
- Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis
- (2011) Georgia Avgerinou et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression
- (2010) G. R. Heiland et al. ANNALS OF THE RHEUMATIC DISEASES
- Psoriasis associated with ulcerative colitis and Crohn's disease
- (2009) AD Cohen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis
- (2008) Luigi Naldi et al. DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now